Leerink Partnrs Estimates Genmab A/S Q3 Earnings

Genmab A/S (NASDAQ:GMAB) – Stock analysts at Leerink Partnrs issued their Q3 2025 earnings per share estimates for shares of Genmab A/S in a research note issued on Thursday, February 13th. Leerink Partnrs analyst J. Chang forecasts that the company will earn $0.43 per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.25 per share. Leerink Partnrs also issued estimates for Genmab A/S’s FY2025 earnings at $1.59 EPS and FY2026 earnings at $1.99 EPS.

Several other equities analysts have also recently issued reports on GMAB. BMO Capital Markets reaffirmed an “outperform” rating and issued a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Finally, Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research note on Thursday, February 13th. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Genmab A/S currently has a consensus rating of “Moderate Buy” and an average price target of $42.17.

Genmab A/S Trading Up 2.2 %

GMAB stock opened at $21.77 on Monday. The stock has a market capitalization of $14.41 billion, a PE ratio of 21.14, a price-to-earnings-growth ratio of 0.54 and a beta of 0.96. Genmab A/S has a 12-month low of $18.64 and a 12-month high of $31.88. The stock’s 50 day simple moving average is $20.64 and its 200 day simple moving average is $23.02.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently modified their holdings of GMAB. EverSource Wealth Advisors LLC increased its stake in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after purchasing an additional 939 shares in the last quarter. Lindbrook Capital LLC increased its stake in shares of Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after purchasing an additional 950 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after purchasing an additional 1,051 shares in the last quarter. Barclays PLC increased its stake in shares of Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after purchasing an additional 2,285 shares in the last quarter. Finally, Cromwell Holdings LLC increased its stake in shares of Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after purchasing an additional 2,496 shares in the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.